HilleVax, Inc. is a pharmaceutical company in the United States with a focus on developing and marketing innovative vaccines. With an ESG score of 28.8, the company is categorized as having a medium risk. HilleVax Inc. specializes in creating virus-like particle (VLP) based vaccines, with their initial program, HIL-214, targeting the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.